MedTrace Logo

A Clinical Study of HRS-7525 Tablets in Patients With Advanced Prostate Cancer

NCT07711184 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 320

Last updated 2026-08-03

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and tolerability of HRS-7525 in participants with Advanced Prostate Cancer, and to determine the dose limiting toxicity (DLT), the maximum tolerated dose (MTD, if possible), and the recommended Phase II dose (RP2D) of HRS-7525.

Conditions

Interventions

DRUG

HRS-7525 tablets

HRS-7525 tablets

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-30
Primary Completion
2028-06-30
Completion
2029-12-31
FDA Drug
Yes

Countries

  • Australia
  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07711184 on ClinicalTrials.gov